Trends in Growth, Segment Analysis, and Competitive Strategies Influencing the Oral Vaccine Market

The oral vaccine sector is poised for notable expansion as advancements in vaccine technology and global health initiatives gain momentum. Increasing investments in research and the growing emphasis on preventive healthcare are paving the way for significant developments in this field. Below is an overview of the expected market size, leading companies, key industry trends, and segmentation details.

Projected Growth and Market Size of the Oral Vaccine Market by 2030
The oral vaccine market is anticipated to grow substantially, reaching a market size of $6.29 billion by the year 2030. This growth corresponds to a compound annual growth rate (CAGR) of 9.7% during the forecast period. The expansion is driven by several factors, including the introduction of innovative oral vaccines such as DNA, RNA, and virus-like particle (VLP) vaccines. Additionally, the widening scope of global immunization programs, the integration of digital health monitoring technologies, increased funding toward vaccine research and development, and a stronger focus on adult as well as travel immunizations are contributing to this market surge. Key trends shaping this growth include the growing use of oral vaccines in pediatric immunization, intensified preventive healthcare efforts, development of live attenuated and subunit oral vaccines, expansion of government-backed vaccination campaigns, and advancements in cold chain logistics for vaccine distribution.

Download a free sample of the oral vaccine market sample:
https://www.thebusinessresearchcompany.com/sample.aspx?id=27373&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Important Drivers Behind Oral Vaccine Market Expansion
A crucial factor fueling the oral vaccine market is the rising adoption of oral vaccines for children, which promotes easier administration and higher vaccine coverage rates. Governments and healthcare organizations worldwide are prioritizing mass immunization programs to control infectious diseases more effectively.
Alongside this, the emphasis on preventive healthcare has increased significantly, with oral vaccines offering a needle-free, patient-friendly alternative that improves compliance and accessibility. The development of novel vaccine types, including second-generation oral pill vaccines, is further enhancing the market's potential by addressing existing limitations of injectable vaccines.

Emerging Companies Making Waves in the Oral Vaccine Market
Several key players are prominent in the oral vaccine industry, including Panacea Biotec Ltd., Zydus Lifesciences, Serum Institute of India Pvt. Ltd., Bharat Biotech Ltd., Haffkine Biopharmaceutical Co. Ltd., Medigen Vaccine Biologics Corp., and BlueWillow Biologics Inc.
In a notable recent development, the International Vaccine Institute (IVI) of South Korea partnered with India's Biological E. Limited in March 2024 to produce a simplified oral cholera vaccine (OCV-S) for both domestic and international markets. IVI provides technical expertise while supporting clinical trials and regulatory approval, aiming to facilitate cost-efficient vaccine production. This technology transfer is expected to be completed by 2025, addressing the increasing global demand driven by rising cholera outbreaks. Biological E. Limited is recognized for its manufacturing capabilities in oral vaccines.

View the full oral vaccine market report:
https://www.thebusinessresearchcompany.com/report/oral-vaccine-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Key Trends Driving Innovation in the Oral Vaccine Sector
Leading companies are focusing on creating next-generation oral vaccines that offer improved immune responses and simplified usa*ge. The development of second-generation oral pill vaccines exemplifies this trend, aiming to enhance immunogenicity and widen protective coverage while eliminating the need for injections or cold chain storage.
For example, in March 2025, U.S.-based biotech firm Vaxart Inc. announced the start of a Phase 1 clinical trial for its second-generation oral norovirus vaccine in pill form. This trial is designed to assess the vaccine's safety and immune efficacy, reflecting the ongoing demand for accessible norovirus immunization. The pill format removes common barriers related to injectable vaccines and supports swift, large-scale distribution during outbreaks.

Comprehensive Segmentation of the Oral Vaccine Market
This report segments the oral vaccine market into vaccine types, applications, and end-user categories:
1) By Vaccine Type:
- Live Attenuated Vaccines
- Inactivated Vaccines
- Subunit Vaccines
- Other Vaccine Types
2) By Application:
- Polio
- Cholera
- Other Applications
3) By End-User:
- Hospitals
- Clinics
- Government Organizations
- Other End-Users

Further breakdown within vaccine types includes:
- Live Attenuated Vaccines such as Oral Polio Vaccine (OPV), Rotavirus Vaccine, Oral Typhoid Vaccine, and Oral Cholera Vaccine
- Inactivated Vaccines like Inactivated Polio Vaccine (IPV), Inactivated Cholera Vaccine, and Inactivated Hepatitis A Vaccine
- Subunit Vaccines including Protein Subunit, Polysaccharide, and Conjugate Vaccines
- Other Vaccine Types comprising Virus-Like Particle (VLP) Vaccines and Recombinant Vector Vaccines

This detailed segmentation provides a clear understanding of the market's structure and highlights the diversity of vaccine options available, supporting targeted development and distribution strategies.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.